Piramal Pharma Solutions (PPS) has announced the implementation of “various tools to unlock API manufacturing capacity and support client needs in drug development and on-patent projects” at its 40-hectare site at Digwal in the Indian state of Telangana. This came shortly after its new API plant at Aurora, Ontario, came online.
Indian-based CDMO Piramal Pharma Solutions (PPS) is to invest about £55 million to expand two sites in the UK. It will expand its antibody-drug conjugate (ADC) capabilities at Grangemouth in Scotland and new API infrastructure at Morpeth in north-east England.
Pharmaceutical CDMO Piramal Pharma Solutions (PPS) is to invest about $32 million to expand its former Ash Stevens API manufacturing site at Riverview, Michigan. This will add 2,300 m2 of space, including 780 m2 of production space.
